PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Noema Pharma raises crucial financing for treatments

The company has raised $112m in order to develop therapies for central nervous system disorders.

Noema Pharma – a company targeting debilitating central nervous system disorders – has announced that it has successfully completed a Series B financing round. The company has subsequently raised $112m from new and existing investors.

The critical round was led by leading European healthcare-focused investment firms Jeito Capital and Forbion. Meanwhile, UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus. Furthermore, Nanna Lüneborg from Forbion, and Rachel Mears from Jeito Capital, will join Noema Pharma’s board of directors.

The financing will be used to develop Noema Pharma’s clinical-stage assets, including its compound basimglurant. The therapy is a mGluR5 inhibitor which is currently being studied in phase 2b clinical trials for severe pain in trigeminal neuralgia and seizures among patients with tuberous sclerosis complex.

Noema is also researching gemlapodect, a PDE10a inhibitor being evaluated in phase 2b clinical trials for Tourette Syndrome and childhood-onset fluency disorder (also known as stuttering). The company is also developing NOE-115, a triple reuptake inhibitor for binge eating disorder and atypical depression.

Luigi Costa, chief executive officer of Noema Pharma, was optimistic about the difference the company’s treatments could have: “We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders,”

He added: “We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”

Nanna Lüneborg, a general partner at Forbion, concluded: “We believe this is the right time to invest as the company has started to generate very encouraging clinical data in indications of high unmet need and particularly with its lead asset basimglurant. We believe Noema to be at the forefront of a significant new wave of innovation in the field of central nervous system disorders which impact millions globally.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026